AstraZeneca: FDA Grants Priority Review to Blood Cancer Drug
August 02 2017 - 2:57AM
Dow Jones News
By Rory Gallivan
LONDON--AstraZeneca PLC (AZN.LN) said Wednesday the U.S. Food
and Drug Administration has granted priority review of the drug
company's application for approval of its blood cancer treatment
acalabrutinib.
AstraZeneca made a new drug application for the treatment after
a Phase II trial.
The FDA grants priority review, which accelerates the assessment
of drugs, to applications for medicines that, if approved, would
offer a significant improvement in the treatment, diagnosis, or
prevention of serious conditions.
Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter:
@RoryGallivan
(END) Dow Jones Newswires
August 02, 2017 02:42 ET (06:42 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
